These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15157754)

  • 1. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
    Papakostas GI; Petersen T; Hughes ME; Nierenberg AA; Alpert JE; Fava M
    Psychiatry Res; 2004 May; 126(3):287-90. PubMed ID: 15157754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine.
    Denninger JW; Papakostas GI; Mahal Y; Merens W; Alpert JE; Nierenberg AA; Yeung A; Fava M
    Psychosomatics; 2006; 47(4):348-52. PubMed ID: 16844895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder.
    Papakostas GI; Petersen TJ; Iosifescu DV; Summergrad P; Sklarsky KG; Alpert JE; Nierenberg AA; Fava M
    J Clin Psychiatry; 2004 Apr; 65(4):543-6. PubMed ID: 15119918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
    Papakostas GI; Petersen T; Sklarsky KG; Nierenberg AA; Alpert JE; Fava M
    Psychiatry Res; 2007 Jan; 149(1-3):195-200. PubMed ID: 17157390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders.
    Serretti A; Mandelli L; Lorenzi C; Pirovano A; Olgiati P; Colombo C; Smeraldi E
    Psychiatry Res; 2007 Jan; 149(1-3):185-93. PubMed ID: 17157919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
    Papakostas GI; Petersen T; Denninger JW; Montoya HD; Nierenberg AA; Alpert JE; Fava M
    Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Migraine: a missing link between somatic symptoms and major depressive disorder.
    Hung CI; Liu CY; Cheng YT; Wang SJ
    J Affect Disord; 2009 Sep; 117(1-2):108-15. PubMed ID: 19167091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
    Yang H; Chuzi S; Sinicropi-Yao L; Johnson D; Chen Y; Clain A; Baer L; McGrath PJ; Stewart JW; Fava M; Papakostas GI
    Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):145-50. PubMed ID: 19572158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
    Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
    J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial.
    Han C; Pae CU; Lee BH; Ko YH; Masand PS; Patkar AA; Jung IK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):437-44. PubMed ID: 17950970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    Ninan PT; Hassman HA; Glass SJ; McManus FC
    J Clin Psychiatry; 2004 Mar; 65(3):414-20. PubMed ID: 15096082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
    Sechter D; Troy S; Paternetti S; Boyer P
    Eur Psychiatry; 1999 Mar; 14(1):41-8. PubMed ID: 10572324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
    Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies.
    Papakostas GI; Stahl SM; Krishen A; Seifert CA; Tucker VL; Goodale EP; Fava M
    J Clin Psychiatry; 2008 Aug; 69(8):1287-92. PubMed ID: 18605812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial.
    Spalletta G; Pasini A; Caltagirone C
    J Clin Psychopharmacol; 2002 Jun; 22(3):263-6. PubMed ID: 12006896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
    Joliat MJ; Schmidt ME; Fava M; Zhang S; Michelson D; Trapp NJ; Miner CM
    J Clin Psychiatry; 2004 Mar; 65(3):373-8. PubMed ID: 15096077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic symptoms in treatment-resistant depression.
    Papakostas GI; Petersen T; Denninger J; Sonawalla SB; Mahal Y; Alpert JE; Nierenberg AA; Fava M
    Psychiatry Res; 2003 May; 118(1):39-45. PubMed ID: 12759160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.
    Bitran S; Farabaugh AH; Ameral VE; LaRocca RA; Clain AJ; Fava M; Mischoulon D
    Int Clin Psychopharmacol; 2011 Jul; 26(4):206-12. PubMed ID: 21278577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
    Demyttenaere K; Albert A; Mesters P; Dewé W; De Bruyckere K; Sangeleer M
    J Clin Psychiatry; 2005 Jul; 66(7):859-63. PubMed ID: 16013901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.